Emergent BioSolutions (Emergent BioSolutions) Book Value per Share : $12.44 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Emergent BioSolutions Book Value per Share?

Emergent BioSolutions's book value per share for the quarter that ended in Dec. 2023 was $12.44.

During the past 12 months, Emergent BioSolutions's average Book Value Per Share Growth Rate was -55.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -23.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -3.80% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 5.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Emergent BioSolutions was 135.90% per year. The lowest was -23.00% per year. And the median was 13.25% per year.

Emergent BioSolutions's current price is $1.92. Its book value per share for the quarter that ended in Dec. 2023 was $12.44. Hence, today's PB Ratio of Emergent BioSolutions is 0.15.

During the past 13 years, the highest P/B Ratio of Emergent BioSolutions was 5.89. The lowest was 0.13. And the median was 2.06.

Emergent BioSolutions Book Value per Share Historical Data

The historical data trend for Emergent BioSolutions's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Book Value per Share Chart

Emergent BioSolutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Book Value per Share

Get a 7-Day Free Trial

21.05

27.25

31.41

27.70

12.44

Emergent BioSolutions Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Book Value per Share	Get a 7-Day Free Trial															27.70	23.86	18.46	13.46	12.44

Competitive Comparison of Emergent BioSolutions's Book Value per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emergent BioSolutions's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's PB Ratio distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's PB Ratio falls into.

Emergent BioSolutions Book Value per Share Calculation

Emergent BioSolutions's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(649	-	0)	/	52
	=	12.44

Emergent BioSolutions's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(649	-	0)	/	52
	=	12.44

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Emergent BioSolutions (NYSE:EBS) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Emergent BioSolutions Book Value per Share Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions (Emergent BioSolutions) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (NYSE:EBS) » Definitions » Book Value per Share

Comparable Companies

Traded in Other Exchanges

ER4:Germany ER4:Germany

Address

400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Executives

Neal Franklin Fowler	director	C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Donald W Degolyer	director	400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
William Hartzel	officer: SVP, Bioservices	400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879
Miller H Haywood Iii	officer: Interim CEO	EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Kathryn C Zoon	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Paul Anthony Williams	officer: SVP, Products Business	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Ronald Richard	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Sujata Tyagi Dayal	director	C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587
Keith Katkin	director	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Glessner Coleen	officer: EVP, Quality & Ethics, and CPL	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Jennifer Lynne Fox	officer: EVP, Ext Aff, GC, Corp Sec	400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879
Richard S Lindahl	officer: EVP, Chief Financial Officer	NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Sue Bailey	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850
Adam Havey	officer: EVP, BioDefense Division	2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853
Robert Kramer	officer: Interim, EVP, BioSciences	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850